Clinical Trials of Repurposed Antivirals for SARS-CoV-2
Miguel Ángel Martı́nez
Abstract
and therapeutic results with other human coronavirus diseases, such as severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). These repurposed drugs have mainly included remdesivir, favipiravir, lopinavir-ritonavir, ribavirin, interferons, and hydroxychloroquine. Unfortunately, the first open-label, randomized, controlled trials are showing poor efficacy of these repurposed drugs. These results highlight the necessity of identifying and characterizing specific and potent SARS-CoV-2 antivirals.
Topics & Concepts
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)2019-20 coronavirus outbreakSars virusBetacoronavirusVirologyMedicineClinical trialCoronavirus InfectionsPandemicAnti-Infective AgentsBiologyMicrobiologyAntimicrobialInfectious disease (medical specialty)OutbreakInternal medicineDiseaseSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesSARS-CoV-2 detection and testing